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There are multiple interventions available that may help to control the development and
spread of resistance to antimicrobial agents in bacteria implicated in community-
acquired respiratory tract infections. Unfortunately, very few studies have assessed
the effectiveness of these interventions using objective end-points, such as reduction in
resistance rates and improvement in clinical outcomes. Most interventions are centered
on reducing inappropriate or unnecessary use of antibiotics; others focus on reducing
disease burden and bacterial colonization. With regard to antibiotic use, efforts should be
concentrated at both the prescriber and consumer levels. Interventions that target
prescribers include: provision of educational materials; strategies and tools to improve
diagnosis; implementation of practice guidelines; personalized interactive sessions with
feedback on the practice proﬁle; and use of delayed prescription and alternative pre-
scribing strategies. Optimal results are usually obtained when these interventions are
combined with consumer education. Regulatory interventions (e.g. licensing regulations
and controlled access to drugs), restrictions in the use of agents for growth promotion in
animals, and use of nonantimicrobial therapies (e.g. probiotics) may help further to
reduce inappropriate antibiotic use and thereby decrease the selective pressure for
development of resistance. Infection-control strategies, public health measures, vaccina-
tion programs, and new antibiotics all have a role in minimizing the spread of resistant
organisms. Ideally, resistance-control programs should include predeﬁned criteria for
success and integral audit processes based on objective end-points (antibiotic use,
resistance trends, and health outcomes). Standardization of data collection is imperative
so that the relative merits of various interventions can be compared. Effective imple-
mentation and audit of interventions is often difﬁcult in developing countries owing to
poor health-care infrastructures, lack of resources, poor education/training, andminimal
regulatory controls on the supply and quality of antimicrobials. Substantial support from
governments and health-care organizations across the globe is required to initiate and
sustain effective intervention programs to control antimicrobial resistance.
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INTRODUCTION
Antimicrobial resistance poses a signiﬁcant global
health problem. To try to tackle this problem, a
large body of knowledge, encompassing areas as
diverse as molecular mechanisms and epidemiol-
ogy to behavioral science, is being accumulated.
The ultimate aim of this research is to identify
means by which resistance can—as a minimum—
be controlled and—at best—be eliminated. The
determination of successful intervention strategies
is pivotal to this aim.
Most commonly, interventions are centered on a
reduction in the volume of antimicrobial use.
However, the relationship between antimicrobial
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use and resistance is complex, and although there
is evidence for a correlation, the threshold at which
clinically signiﬁcant resistance occurs remains
unknown. A quantitative relationship has been
proposed by mathematical modeling using popu-
lation genetic methods and epidemiologic obser-
vations [1]. It would be simplistic, however, to
conclude that the absolute volume of antibiotic
use is solely responsible for resistance selection.
Other factors that may also be important in the
selective process include: the transmissibility of
resistance determinants within and between spe-
cies and genera; varying bacterial mutation rates;
dose and duration of antibiotic therapy; and
variations in clonal spread through cultural and
lifestyle differences between populations. The
challenge for those researching in this area is to
determine which of these factors play pivotal roles
and, thereby, to identify the most productive
directions for intervention strategies to control
resistance.
Many interventions to control resistance have
been suggested and implemented, some with-
out direct evidence that the target activity does
in fact lead to resistance. This paper ﬁrst outlines
the tools used to audit the impact of these inter-
ventions. It then reviews a wide range of interven-
tions, assessing the means by which they have
been audited and the results obtained. These inter-
ventions are broadly divided in to those concern-
ing antibiotic use and those concerning disease
burden and colonization. Finally, this paper dis-
cusses problems associated with implementing
and auditing interventions in low-resource
countries.
It is not the intention of this paper to cite all
research published to date. Rather, selected stu-
dies that are representative of the overall body of
work are reviewed.
MONITORING THE IMPACT OF
ANTIMICROBIAL RESISTANCE
CONTROL INTERVENTIONS
Audit is essential to measure the success of inter-
ventions designed to reduce antimicrobial use
and resistance, and improve health outcomes.
Many interventions are initiated before the end-
points for success, the magnitude of the response
that is considered clinically meaningful, or the
time over which the response is expected have
been established. Moreover, measurement of
speciﬁc resistance determinants before and after
the intervention is rarely performed. Without
these measurements, comparison of the relat-
ive merits of various interventions is not pos-
sible. Reasons for the failure of an intervention
can also be understood if the correct data are
collected.
Interventions designed to control antimicrobial
resistance can be audited for their effects on:
 Antibiotic use;
 Resistance rates;
 Health outcomes.
Antibiotic use
Standardization of data collection on antibiotic
use is essential. The World Health Organization
(WHO) has established both a classiﬁcation system
and a unit of measurement, the deﬁned daily
dose (DDD)/1000 population/day to describe anti-
biotic use [2]. The DDD is often a compromise be-
cause dosing schedules differ between countries.
However, it does provide a standard that allows
comparisons between and within countries [3]. In
hospitals, where a different denominator is neces-
sary, antibiotic usage is expressed as DDD/100
occupied bed days. Some studies have used
raw import or institutional use volumes, and
although some impression can be obtained regard-
ing the direction of change following an interven-
tion, quantiﬁcation is not possible where these
data are used. Other studies have used the number
of prescriptions/ofﬁce visit or the prescription
rate/1000 population. These measurements con-
tain variables, such as dose size and duration of
therapy, and hence provide less meaningful
results.
The DDD classiﬁcation system is not perfect as it
is based on the average standard dose for themajor
indication in question and may not reﬂect the
actual or recommended dose or that used for other
indications. In addition, it does not take into
account loading or prophylactic doses and it
assumes patient compliance. Speciﬁc data collec-
tion is necessary to establish use by age group or
indication. If antibiotic use in control and inter-
vention groups is measured during different time
periods, correlation with disease incidence or pre-
valence must be considered.
Standardization of antibiotic use data in animals
is much more difﬁcult and an acceptable system
has yet to be devised.
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Resistance surveillance
Antimicrobial resistance surveillance, the princi-
ples of which are reviewed in detail in another
chapter of this Global White Paper [4], is an essen-
tial tool in the measurement of the effectiveness of
any intervention strategy. There are, however,
considerable difﬁculties in setting up an optimum
surveillance program [4].
Ideally, surveillance needs to encompass both
human and animal bacterial isolates. However,
the latter are more difﬁcult to monitor because
veterinary laboratories do not perform ‘routine’
cultures and susceptibility testing regularly.
Recommendations have been made for the key
indicator organisms that should be included in
animal surveillance studies. The Ofﬁce Interna-
tional des Epizooties (OIE) has proposed that
speciﬁc animal pathogens, zoonotic pathogens
(Salmonella spp., Campylobacter spp.) and commen-
sal organisms (Escherichia coli, enterococci) should
be monitored [5].
Human health surveillance programs can be
passive or targeted. The use of passively acquired
data (obtained from routine testing in clinical
laboratories) has a number of potential weak-
nesses. For the data to be valid, it is necessary that:
 Standardized susceptibility testing methods,
such as those recommended by the National
Committee for Clinical Laboratory Standards
(NCCLS) [6], British Society for Antimicrobial
Chemotherapy (BSAC) [7], Deutsches Institut
fu¨r Normung (DIN) [8], or Socie´te´ Franc¸aise de
Microbiologie (SFM) [9], are used. So that results
from the different methods can be compared,
external quality assessment is necessary to cor-
relate the data [10] and to establish the proﬁ-
ciency of the submitting laboratories [11].
 The data do not contain repeat isolates from
individual patients.
 Clinical specimen data are separated from
‘screening’ data.
 Indicator isolates are identiﬁed and an appro-
priate range of antimicrobials is tested.
 Speciﬁcpatient groups (e.g. patients in intensive-
care units [ICUs], long-term care patients, pedia-
tric patients) are identiﬁed.
 The denominator is established and standar-
dized. Ideally, this should be the number of
infected patients. However, most often it is
the total number of organisms tested by the
laboratory.
Some of the disadvantages of passive surveil-
lance are that [12]:
 The data may be skewed because patients with
failed therapy are more likely to be tested.
 There may be an age bias (the elderly and very
young being disproportionately represented).
 Isolates from particular disease states may be
included disproportionately, e.g. patients with
chronic obstructive pulmonary disease are more
likely to provide a specimen than patients with
community-acquired pneumonia.
 The data are more likely to be based on prede-
ﬁned susceptibility breakpoints (i.e. reported as
‘sensitive’ or ‘resistant’), rather than minimum
inhibitory concentrations (MICs), which permit
comparisons to be made across studies. This
means that more subtle changes in susceptibility
will not be identiﬁed.
Some studies have been conducted to assess the
reliability of data obtained by passive surveillance.
In a UK study, susceptibility proﬁles of E. coli
isolates from 220 laboratories obtained using a
variety of methods were compared with those
obtained at a specialized laboratory. Resistance
trends were similar, but there were some minor
discrepancies in annual resistance ﬁgures that
could be explained by geographic bias and differ-
ences in the breakpoints used [13]. An external
quality assessment program conducted in the UK
and Europe to challenge laboratory testing meth-
ods revealed problems with the detection of low-
level resistance in some laboratories. These pro-
blems may be due, in part, to the selection of
bacterial susceptibility breakpoints [10]. This high-
lights the fact that breakpoint measurements must
be standardized if national resistance trends are to
be compared following international intervention
measures. Targeted surveillance is able to address
some of these problems associated with passive
surveillance. However, targeted surveillance is
more difﬁcult to conduct and to maintain.
Surveillance studies tend to focus on measuring
resistance phenotypically, i.e. according to the
expression of resistance by isolates. For some
interventions, it may also be necessary to establish
the genetic basis of resistance to demonstrate clo-
nal spread or to detect ﬁrst-stage mutants. Geno-
typic analysis may also explain failure of the
intervention because of co-selection by other anti-
biotics or because of persistence of the resistant
determinant in the population under study [14]. If
all these factors are taken into consideration, and
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data collection is tailored for a speciﬁc interven-
tion, surveillance can be an effective audit tool.
Health outcomes
The standard health outcomes measured in
respiratory tract infections (RTIs) are mortality
and morbidity. When measuring mortality as an
end-point, the natural history of the disease and
co-morbidities need to be considered. Morbidity
measurements are more common and include
quality of life, time off work/school, complication
rates, requirements for alternative therapy, specia-
list referral, hospitalization, number of physician
visits, number of investigations, length of hospital
stay, ICU admissions, infection-control costs, and
days to defervescence [15]. Standardization
between the intervention groups is essential for
severity of illness, prior exposure to antibiotics,
age, presence of invasive devices, and underlying
medical conditions [16].
RESISTANCE-CONTROL
INTERVENTIONS: ANTIBIOTIC USE
Most interventions to reduce bacterial resistance to
antibiotics and improve health outcomes are tar-
geted at antibiotic use. The ultimate aim of all of
these interventions is to increase the appropriate-
ness of prescribing and thereby reduce the volume
of antibiotic use. Figure 1 shows the pathways
linking antibiotic use, bacterial resistance, and
health outcomes, and indicates the areas where
most interventions have been attempted. Most
strategies are targeted at inappropriate or unne-
cessary use of antibiotics, particularly for the treat-
ment of RTIs as this accounts for 75–80% of
antibiotic prescribing in the community [17,18].
The options for intervention to reduce antibiotic
use are numerous and include:
 Prescriber interventions, e.g. improved diagno-
sis, implementation of practice or prudent anti-
biotic-use guidelines, ‘practice proﬁling’ and
feedback, education programs, and use of
delayed prescription;
 Consumer interventions, which provide educa-
tion on antibiotic therapy and resistance;
 Regulatory interventions, e.g. drug licensing
regulations and controlled access to antibiotics;
 Restricting use of antibiotics in animals for
growth promotion, prophylaxis, and therapy
through regulatory control, improved disease
management, use of alternatives to growth pro-
moters, implementation of prudent use guide-
lines and improved dosing schedules.
Where antimicrobial therapy is essential, pre-
scribing strategies can be modiﬁed to reduce the
selective pressure for resistance. Themodiﬁcations
include the determination of optimum dosing
regimens, restrictions applied to particular anti-
biotics, and use of antibiotic cycling.
Prescriber interventions
Many different bodies, including government
organizations, learned societies, hospital adminis-
trations, and health-management organizations,
can initiate interventions targeted at prescribers.
These interventions can take various forms.
Improved diagnosis
Improved diagnosis of bacterial infections can be
achieved using laboratory tests, including those
that provide a rapid same-day/ofﬁce answer, or
by applying prediction rules or clinical scoring
systems. The latter approach has been evaluated
in a study that assessed the validity of a scoring
system to predict Streptococcus pyogenes sore throat
in family practice in Canada [19]. The scoring
system used was found to be more sensitive than
physician judgement for identifying infection with
Group A streptococci. Indeed, if patients had been
managed according to these guidelines, a 52.3%
reduction in antibiotic prescriptions would have
resulted.
Rapid and reliable diagnostic tests that can be
performed easily at the point of prescribing (with
an accompanying quality assurance program) are
not yet readily available. In Denmark, microscopy
Figure 1 Relationship between antibiotic use, disease
colonization, infection, health outcome and antibiotic
resistance, and targets for resistance control interventions.
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on urine or genital specimens and antigen testing
for GroupA streptococci are performed by general
practitioners, but there has been no formal assess-
ment of whether this reduces antibiotic prescrib-
ing or the prevalence of resistance [20]. This is an
area deserving further research and audit.
Practice or prudent-use guidelines
In general, clinical guidelines have been shown to
improve medical practice [21]. Many learned
societies, government agencies and other bodies
have provided guidelines for the ‘appropriate’ use
of antimicrobials. Many of these guidelines were
initially developed to control the expanding cost of
health care. Now the focus is on ‘evidence-based’
best practice where possible, with a greater
emphasis being placed on minimizing resistance
selection by reducing antimicrobial prescribing.
Many of the guidelines are designed to limit anti-
biotic use for infections that are not bacterial or
that are self-limiting. In 1995, the US Centers for
Disease Control (CDC) initiated the publication of
educational materials for patients and physicians
treating RTIs in children, and later published these
guidelines [22]. An audit carried out by the CDC
showed that the annual rate at which ofﬁce-based
physicians prescribed antibiotics for infectious
RTIs (otitis media, common cold, bronchitis,
sinusitis and pharyngitis) in children aged <15
years decreased by 44% (P< 0.001) for prescrip-
tions/1000 children and by 14% (P< 0.001) for
prescriptions/1000 ofﬁce visits between 1989/
1990 and 1999/2000 [23]. This reduction in anti-
biotic prescribing coincided with increased aware-
ness of antibiotic resistance among physicians.
Although encouraging, this study was retrospec-
tive and therefore unable to control for population
variation, Haemophilus inﬂuenzae type B vaccine
uptake and day-care participation rates.
The CDC recently convened a panel of physi-
cians to formulate guidelines for the treatment of
upper RTIs in adults [24] (including nonspeciﬁc
infections [25,26], sinusitis [27,28], acute pharyn-
gitis [29,30], and acute bronchitis [31,32]). Only
recently published, these have not yet been
audited for their effects on prescribing or resis-
tance. Other organizations that have produced RTI
guidelines include the American Thoracic Society
[33,34], the Infectious Diseases Society of America
[35], the Canadian Infectious Diseases Society
together with the Canadian Thoracic Society
[36], the European Respiratory Society [37], and
the British Thoracic Society [38]. Audit is essential
if the value of these guidelines is to be assessed.
Despite this, audit is not routinely incorporated
into guidelines. Some assessments of adherence
and the effect of guidelines on clinical outcome
have been reported [39], but these have not spe-
ciﬁcally looked at antibiotic prescribing or resis-
tance prevalence.
Other audited prescriber interventions have
been reported. A prospective German study on
1010 patients examined the guideline-inﬂuenced
effect on prescribing, and clinical outcome, for two
primary-care physicians [40]. The intervention,
received by one physician consisted of manage-
ment guidelines for sore throat. The second phy-
sician received no intervention. Retrospective data
were also examined for both physicians. The phy-
sician subjected to the intervention showed
decreases in the frequency of throat swabs (from
32% to 7%) and in antibiotic use (from 51% to 31%).
Interestingly, clinical outcome (in terms of success
and relapse rates) remained the same before and
after the intervention and between the two phy-
sicians. In a second study, an antibiotic manage-
ment program, which used local clinician-derived
consensus guidelines embedded in a computer-
assisted decision-support system, was assessed for
its impact on clinical outcomes, patterns of anti-
microbial resistance, and antibiotic usage (mea-
sured in DDD/100 occupied bed days) [41].
Measures of antibiotic use and clinical outcomes
improved during the 7-year study period. Anti-
biotic use decreased by 22.8%, appropriate timing
of presurgical prophylaxis increased from 40% to
99.1%, the rate of antibiotic adverse events
decreased by 30%, and the mortality rate
decreased from 3.7% to 2.7%. Antibiotic resistance
patterns remained stable during the study period.
The same group reported a reduction of antibiotic
use from 23.6 to 11.4 DDD/100 occupied bed days
following the application of a computer-assisted
management program in an ICU; resistance was
not studied [42]. Although these data appear con-
vincing, these studies were observational, and it is
possible that the changes reported could have been
a result of other institutional practices.
Practice profiling and feedback
Practice proﬁling involves the acquisition of indi-
vidual practitioner prescribing data, usually from
national databases, which are then compared with
peer practices or the group norm. The information
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is then fed back to the prescriber with the intention
of highlighting deviations from the normal pre-
scribing pattern. Studies have shown a lack of
effect of practice proﬁling performed in isolation
on prescribing practices [43,44]. However, when
combined with an educational component (e.g.
targeted mailed material and outreach visits), an
improvement in prescribing practice has been
demonstrated compared with control groups
[43,45,46].
Education programs
Educational programs for medical practitioners
include provision of ofﬁce-based material (e.g.
posters, information sheets, evidence-based prac-
tice guidelines, alternative nonprescription pads),
academic detailing (i.e. personal, interactive edu-
cational visits), problem-oriented case studies,
seminars, and small group discussions managed
by opinion leaders. Combinations of some or all of
these educational tools have reduced or improved
the quality of antibiotic prescribing in primary care
[47–50], reduced antibiotic prescription rates in the
treatment of speciﬁc infections such as acute bron-
chitis [51], and decreased the use of speciﬁc agents
in the hospital setting [52].
Delayed prescription
The strategy of providing a prescription to be
dispensed if clinical improvement has not
occurred within 24–48 h has been used in the
management of acute otitis media. Acute otitis
media is mainly self-limiting and symptomatic
relief is often all that is required [53,54]. In one
study, introduction of this delayed-prescription
approach resulted in a 19% reduction in antibiotic
use compared with a similar period during the
previous year [53]. This approach has also been
assessed as a means of ensuring patient satisfac-
tion in the treatment of mainly viral upper RTIs,
where patients often expect to receive a prescrip-
tion [55]. Patient satisfaction was high (96%) and
the dispensing rate of the delayed prescriptions
was 50%, resulting in an overall reduction in
antimicrobial therapy for these infections.
Multifaceted physician-directed interventions
Two systematic reviews have concluded that the
most effective approach for improving antimicro-
bial use is a combination of all of the preceding
strategies. A Cochrane review was conducted to
assess the effects of interventions to improve the
delivery of preventive services in primary care.
This review was not speciﬁcally directed at stra-
tegies to reduce antimicrobial prescribing, but
rather at the effectiveness of the various interven-
tion models [56]. The second review was restricted
to implementation methods to improve antimicro-
bial use and assessed both multifaceted and indi-
vidual intervention strategies [57].
Consumer interventions
Consumer interventions are educational in nature
and can be introduced at various levels. Types of
intervention include the use of written material
(posters, pamphlets, educational sheets); prescri-
ber explanation and increased consultation time;
and presentations at day-care centers, community
organization meetings, schools, and primary
health-care centers. In addition, coverage of the
issues in both print and television media can
achieve wide penetration of the community. A
recent study has shown that a multifaceted con-
sumer education program changed public aware-
ness about antibiotic resistance and indications,
with the result that the proportion of parents who
expected antimicrobial therapy for their child
declined in the intervention area while it increased
in the control population [58]. Other studies
reported a decrease in antibiotic prescribing fol-
lowing a program aimed at both the prescriber and
the consumer [50,51,59]. For example, implemen-
tation of a public education program consisting of
consumer booklets, prime-time television adver-
tising, websites, letters to general practitioners,
and pharmacists conducted in Belgium in 2000
decreased total antibiotic sales by 10% compared
with the corresponding period in the previous
year [59]. The mean monthly reduction in antibio-
tic sales was signiﬁcantly larger than any decrease
caused by variations in the incidence of acute RTIs.
However, the decrease was transient and antibio-
tic prescribing rates returned to previous levels
within a short period. A planned repetition of the
program should be able to assess whether these
changes can be sustained.
Regulatory interventions
Drug licensing
Guidance issued by the European Agency for
the Evaluation of Medicinal Products (EMEA)
recommends that assessment for registration of
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antibiotics should include resistance selection
data, resistance prevalence data applicable to the
target population, a requirement for regular
updating of resistance prevalence data in the pro-
duct information document, and restriction of
prescribing indications [60]. The use of pharma-
codynamics to establish optimum dosing regi-
mens is also recommended [61]. Although the
European Union (EU) and Australian regulatory
authorities have accepted these recommendations
in principle, they have yet to be fully implemented.
In addition, there is currently no formal mechan-
ism for evaluating the impact of these require-
ments on antimicrobial use or resistance
patterns. Other licensing issues relevant to resis-
tance control include the need for a mechanism to
evaluate generic antimicrobials for acceptable
bioavailability and potency and to detect and
eliminate counterfeit antimicrobials.
Access to antimicrobials
Access to antimicrobials varies greatly between
countries. In some countries, access is restricted
through a physician prescription system, while in
others the consumer can buy antimicrobials
directly over the counter from pharmacies. Con-
trolling access to antimicrobials is an important
way of limiting inappropriate use of these agents
and regulation to ensure better control is required
in many developing countries. A control mechan-
ism used by some countries is the method of
payment. Direct government cost subsidies inﬂu-
ence the availability and total usage of antimicro-
bials and may thereby affect resistance. In two
countries, actions taken through drug subsidies
have affected antibiotic use. In Iceland, the
removal of government subsidies for antimicro-
bials was followed by a decrease in the volume of
antibiotic use and in the level of resistance in
Streptococcus pneumoniae [62]. Education programs
aimed at prescribers and consumers were imple-
mented concomitantly and hence it is difﬁcult to
determine the relative contributions of the inter-
ventions to this effect. In Australia, the govern-
ment subsidizes some antimicrobials in
community practice. For RTIs these are penicillin,
amoxicillin, ﬁrst-generation cephalosporins and
macrolides. These are the antibiotics to which
S. pneumoniae is most commonly resistant in Aus-
tralia [63]. In contrast, there is a low level of
resistance to the newer ﬂuoroquinolones, which
have a very restricted license that does not allow
widespread use for community-acquired infec-
tions. Other than in methicillin-resistant Staphylo-
coccus aureus (MRSA), ﬂuoroquinolone resistance
in other organisms is also low [64]. Antibiotic use
data (DDD/1000 population/day) conﬁrm high
use of the subsidized drugs and low consumption
of ﬂuoroquinolones in Australia [65].
Animal use
The widespread use of antimicrobials in animals
for growth promotion, prophylaxis and therapy
has led to the emergence of resistance. This resis-
tance has the potential to affect human health.
Multiply resistant salmonellae and ﬂuoroquino-
lone-resistant Campylobacter jejuni are recognized
causes of zoonotic infection. Resistance in the
normal intestinal ﬂora of poultry and swine has
also been documented. In particular, vancomycin-
resistant enterococci (VRE), streptogramin-resis-
tant enterococci, and ciproﬂoxacin-resistant E. coli
have been associated with the use in animals of
avoparcin, virginiamycin and enroﬂoxacin, respec-
tively. Transfer of genes conferring resistance to
antimicrobials not used in human medicine (e.g.
nourseothricin, apramycin and hygromycin) has
also been shown to occur from animal bacteria to
organisms that are commensal or pathogenic in
humans [66]. Various organizations [WHO, OIE,
Committee for Veterinary Medicinal Products
(CVMP), House of Lords] have assessed the avail-
able data and have concluded that antimicrobial
use in animals is creating a reservoir of resistant
organisms and genes that may have a signiﬁcant
impact on human health. Many strategies have
been put forward to decrease the use of antimi-
crobials in animals. However, audit data have
been reported for very few speciﬁc interventions.
Regulatory control
Use of avoparcin as a growth promoter was ban-
ned in Sweden (1986), Denmark (1995), Germany
(1996), and subsequently in all EU member states
(1997). Further bans were introduced in the EU on
the use of virginiamycin, tylosin, spiramycin and
bacitracin in 1998. There are now some data show-
ing a decrease in vancomycin resistance in enter-
ococci isolated from poultry following this action.
In the 18months following the ban there were
reductions in Denmark (from 82% in 1995 to
12% in 1998) [67], Germany (from 100% in 1994
to 25% in 1997, coupled with a decrease in VRE in
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human fecal samples from 12% to 3%) [68], and
Italy (from 14.6% to 8%) [69]. Comparisons of
resistance rates in fecal indicator bacteria (E. coli
and enterococci) in pigs between The Netherlands
(1995/1996) and Sweden (1997) showed a lower
prevalence for most antibiotics, in particular for
vancomycin (39% vs. 0%), in Sweden. These var-
iations reﬂected differences between the countries
in antibiotic usage [70].
Improved disease management
Growth promotion provided by antimicrobials is
due, in part, to the control of intestinal infections,
e.g. necrotic enteritis in poultry and postweaning
diarrhea in pigs. Prevention of these diseases by
alternative strategies can provide the same, if not
greater, economic advantages. Alternative strate-
gies include total or partial exclusion of pathogens
(including speciﬁc pathogen-free production),
vaccination, and improvements in animal husban-
dry [71]. Indeed, employment of all or some of
these measures in Sweden and other Scandinavian
countries has resulted in reduced antimicrobial
consumption. However, it is very difﬁcult to com-
pare the relative beneﬁt between countries as there
is no standard means of comparing consumption.
The use of the ratio of volume of antimicrobials
used to estimated live weight of animals slaugh-
tered is of partial use, but this does not take into
account antimicrobial use in companion animals
and other variables [72].
Alternatives to growth promotants
Probiotics (see later section) have been investi-
gated as an alternative to antimicrobials to provide
the equivalent weight gain [73], and to reduce dis-
ease burden [74] and carriage of pathogenic bac-
teria prior to slaughter [75,76]. Studies showing
the effect of probiotics on antimicrobial use and
resistance reduction in animals have not been
found.
Prudent-use guidelines
Implementation of guidelines for antimicrobial
use in animals as recommended by the WHO
[77] has not been reported. It is reasonable to
conclude that this process will be subject to the
same adherence problems seen in human health.
Improving dosing schedules
As with human health, pharmacodynamic studies
(see later section) can provide a rational basis for
antibioticdosing in animals [78].Given thedifferent
pharmacokinetics in the various animals requir-
ing treatment, much research is necessary before
any controlled intervention studies can be per-
formed.
Prescribing strategies
Many interventions to control resistance are aimed
at reducing the use of antimicrobials in situations
where there is little or no clinical beneﬁt to be
gained. There are, however, many clinical situa-
tions where antimicrobial therapy is essential for
the well-being of the patient. It is therefore impor-
tant to identify and encourage strategies whereby
appropriate antimicrobial usage exerts the least
selective pressure. In these situations, audit should
be directed at resistance prevalence or at the level
of resistance gene detection.
Pharmacodynamic dosing
Pharmacodynamic dosing studies have advanced
our understanding of the factors that determine
appropriate antibiotic doses and dosing intervals
to achieve optimal clinical efﬁcacy [79,80]. For b-
lactam and macrolide antibiotics, efﬁcacy is asso-
ciated with the time that serum antibiotic concen-
trations remain above the MIC of the organism.
For ﬂuoroquinolones and aminoglycosides, efﬁ-
cacy most closely correlates with the ratio between
the area under the concentration–time curve
(AUC) and the MIC. Furthermore, in vitro and
in vivo pharmacodynamic models have been used
to establish dosing regimens that will minimize
resistance selection and mutation frequencies [81–
86]. For ﬂuoroquinolones, a maximum plasma
concentration (Cmax)/MIC ratio >10 reduces the
selection of resistant organisms [82]. These ﬁnd-
ings have been conﬁrmed clinically in a study in
acutely ill patients [87]. However, further clinical
studies are required in this area.
Pharmacodynamic studies can also be used to
determine optimal therapeutic regimens to red-
uce the carriage of resistant organisms. For exam-
ple, nasopharyngeal colonization with resistant
S. pneumoniae during therapy for RTIs has been
described [88,89]. Eradication of these bacteria
during therapy has been suggested as necessary
not only for optimum clinical outcome but also to
reduce the spread of resistant organisms [90,91].
The use of low doses and long treatment durations
with b-lactam antimicrobials contributes to the
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selective pressure for pharyngeal carriage of resis-
tant S. pneumoniae [92]. Conversely, short-course,
high-dose amoxicillin therapy for RTIs in children
has resulted in a small, but signiﬁcant reduction in
the carriage of resistant strains 28 days after treat-
ment [93]. Differences between classes of antimi-
crobials have also been studied, with amoxicillin—
clavulanate being superior to azithromycin in era-
dicating resistant S. pneumoniae [94].
Optimization of antimicrobial doses through
pharmacodynamics is a promising area for future
intervention studies using agents currently in use,
and these studies should be incorporated into
the discovery and development phases of drug
research and in the registration of new agents
[95].
Restricting use of antibiotics
Restricting or reducing the use of a single anti-
biotic has failed to result in the loss of resistance.
Resistance can persist for many months after
the cessation of use of an antibiotic [96], and for
many years [97,98] if the resistance determinant
is linked to genes or transposons conferring resis-
tance to other agents in continued use. Never-
theless, restriction coupled with a requirement
for authorization to use certain parenteral antibio-
tics resulted in decreased resistance to b-lactam
and ﬂuoroquinolone antibiotics in one hospital-
based study. The clinical outcomes of mortality,
time to receipt of appropriate antibiotics, and dis-
charge from hospital were not adversely affected
[99].
More success has been achieved by restricting
whole classes of antibiotics during outbreaks of
diseases caused by speciﬁc resistant organisms.
Restriction of third-generation cephalosporins
and substitution with a b-lactam/b-lactamase
inhibitor was effective in controlling VRE coloni-
zation [100,101] and cephalosporin resistance in
nosocomial Klebsiella [102]. Similarly, substitution
of cephalosporins with a carbapenem was shown
to control another nosocomial Klebsiella outbreak.
However, this intervention resulted in the emer-
gence of carbapenem-resistant Pseudomonas [103].
In a further study, restriction of third-generation
cephalosporins was associated with the termina-
tion of a multiresistant Acinetobacter baumannii
outbreak [104]. In all these studies, additional
infection control measures were introduced, mak-
ing the relative contribution of class restriction and
infection control difﬁcult to assess.
Antibiotic cycling
The concept of rotating empiric antibiotic regi-
mens as a means of reducing and/or preventing
resistance selection was initiated by Gerding
[105,106], who published 10 years’ experience of
alternating between amikacin and gentamicin.
At the start of the study period, levels of genta-
micin resistance were high. After a switch to ami-
kacin, aminoglycoside resistance levels fell, only to
rise rapidly on the re-introduction of gentamicin.
This increase in resistance did not occur after a
second cycle of amikacin, when gentamicinwas re-
introduced at a much slower rate. In this study, the
reduction and maintenance of low resistance
levels coincided with the loss of the resistance
determinant (a plasmid carrying one of the ami-
noglycoside-inactivating enzymes) from Gram-
negative organisms in the environment and in
patients. Following this report, the use of antimi-
crobial ‘cycling’ as a successful intervention has
gathered momentum [107,108].
Despite these promising results, some of
the studies used to support the concept of anti-
biotic cycling [109–112] leave questions unan-
swered. Indeed, two of the studies practised
antimicrobial class substitution rather than rota-
tion.The outcomes measured in these studies
were the incidence of ventilator-associated pneu-
monia as a result of antibiotic-resistant bacteria
[109,111] and inadequate treatment as a result
of organism resistance [110]. These studies did
not report full resistance trends before, during,
or after the study, and resistance mechanisms
were not investigated. Therefore, it is possible that
selection of organisms with multiple resistance
mechanisms could occur if this strategy was
employed without careful monitoring [113,114].
Models for studying antimicrobial cycling have
been proposed [106,115]. Thus, detailed, care-
fully controlled, multicenter studies are requi-
red before this intervention can be considered
successful.
RESISTANCE-CONTROL
INTERVENTIONS: DISEASE BURDEN
AND COLONIZATION
Although most resistance-control interventions
aim to improve antibiotic use, resistance can also
be targeted using other interventions concerned
with disease burden and colonization. These inter-
ventions include:
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 Public health measures, e.g. day-care exclusion
and improved sanitation.
 Infection control in hospitals, e.g. improved
hand hygiene, use of barrier precautions, and
implementation of decontamination protocols to
reduce carriage of resistant organisms.
 Vaccination programs.
 Use of alternative nonantimicrobial therapies.
Public health measures
Day-care exclusion
A number of studies have identiﬁed prior anti-
biotic use [88,116], and attendance at a day-care
center [117–119] or other ‘overcrowded’ circum-
stances [120] as major risk factors for the carriage
and spread of resistant S. pneumoniae. Using math-
ematical modeling, a critical review of the relation-
ship between antibiotic use and carriage of
infection with resistant pneumococci has provided
further support for the importance of the selective
pressure of antimicrobial therapy [121]. This
model showed that antibiotic treatment substan-
tially increases a patient’s risk of carrying/being
infected by penicillin-resistant S. pneumoniae com-
pared with penicillin-susceptible strains. Further-
more, superinfection with resistant S. pneumoniae
from the nasopharynx has been shown to follow
antibiotic treatment for otitis media and to result in
treatment failure [122]. Recognizing that carriage
and spread of resistant pneumococci is related to
day-care attendance has led to a unique interven-
tion program in Sweden [123]. Children in day-
care centers found to be colonized or infected with
penicillin-resistant S. pneumoniae were excluded
from attendance. All contacts were followed up
and, if cultures proved positive, they were also
excluded. The cost of exclusion (including costs of
alternative day-care placement and parents’
absence from work) was funded by the govern-
ment. The median duration of carriage was found
to be 19 days. In a limited number of cases, deco-
lonization was achieved by the use of rifampicin in
combination with another agent. Unfortunately,
the end-point of the study, as reported, is not
deﬁned. The monthly number of resistant S. pneu-
moniae cases and contacts is provided, but the
denominator is unclear. The ﬁnal evaluation of
the intervention has not yet been published. How-
ever, the simultaneous introduction of a program
to reduce antimicrobial use, which resulted in
a 24% reduction in consumption (DDD/1000
inhabitants for selected respiratory antibiotics),
will make interpretation of the outcome difﬁcult.
Sanitation
Multidrug-resistant strains of Salmonella typhi
[124] and Vibrio cholerae [125] have been respon-
sible for outbreaks of disease in the developing
world. Resistance to ampicillin, chloramphenicol,
trimethoprim, sulfonamides and tetracyclines has
become common in these organisms and more
recently ﬂuoroquinolone resistance has been
reported in both species [126,127]. As these infec-
tions are food- and water-borne, improved sanita-
tion and food hygiene may be the most important
resistance control mechanisms. For example, a
surveillance study in Peru showed that patients
with cholera were less likely to have access to
municipal water, sewage systems, or adequate
toilet facilities than those with acute diarrhea
not caused by cholera [128]. Nevertheless, a reduc-
tion in antimicrobial resistance as a direct result of
improved sanitation has not been reported.
Infection control in hospitals
There are two important aspects to the control of
antimicrobial resistance in hospitals and long-
term-care facilities. Firstly, the emergence of resis-
tance is related to the use of antimicrobials. The
interventions described above, aimed at prescri-
bers and the way in which antimicrobials are used,
are equally applicable in the hospital setting and in
the community. Secondly, once resistance has
emerged or entered a hospital from the commu-
nity [129,130], it extends through clonal spread or
genetic transfer via transposons and plasmids. The
implementation of basic infection control practices
(improved hand hygiene and the use of barrier
precautions and decontamination protocols to
eliminate carriage of resistant organisms) is central
to the prevention of this dissemination.
Hand hygiene
The efﬁcacy of hand washing in preventing the
transmission of organisms between patients is well
established [131]. However, hand washing is still
not performed adequately in routine practice
[132]. Interventions designed to improve the fre-
quency and acceptability of hand washing for
every patient contact include education programs
and the use of alcohol-based hand-washes [102].
The routine use of surgical gloves has also been
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implemented as an alternative approach to reduce
bacterial transmission between patients [133].
These hand-hygiene approaches have been eval-
uated using a variety of end-points, including
adherence to the intervention, hand colonization
rate, and rate of nosocomial infection. The results
of educational programs have been disappointing
[134,135]. In one ICU-based study, no signiﬁcant
improvement in hand-washing compliance was
shown before and after an educational interven-
tion (22% vs. 25% in the medical ICU and 13% vs.
14% in the cardiac ICU). The use of an alcohol-
based hand-wash has been shown to increase
compliance, but only to a maximum of 48%
[135]. None of the published studies has deﬁned
the rate of hand washing required for effective
infection control. This rate may be difﬁcult to
establish as it may vary between different patient
populations (e.g. the severely immunocompro-
mized, those with intravascular lines, and those
in the ICU), and the number of patients colonized
with a resistant organism [136]. Mathematical
modeling suggests that the level of compliance
with hand washing needs to be considerably
higher than reported levels to prevent nosocomial
transmission of VRE in endemic settings [137].
Therefore, based on the studies to date, the opti-
mum intervention for limiting bacterial transmis-
sion via hand contact has yet to be determined.
Barrier precautions
Barrier precautions and separation of patients and
staff into cohorts have been shown to be effective if
all those infected and colonized are identiﬁed.
Geographic isolation is widely practiced and has
been demonstrated to reduce rates of bacteremia in
a burns unit [138] and the rate of MRSA in clinical
specimens from an ICU [139]. The use of surgical
gloves has been successful in reducing the rate of
transmission of MRSA within a neonatal ICU set-
ting [140]. In addition, universal surgical glove
usage has been shown to reduce the rate of noso-
comialClostridiumdifﬁcile-associateddiarrhea [141].
Decontamination protocols
Patients are the main reservoir of resistant organ-
isms in hospitals and speciﬁc screening programs
are required to detect all carriers. Warren & Fraser
[142] recently reviewed studies of interventions
designed to eliminate the carriage of resistant
organisms and thereby limit the spread of resis-
tance. The use of topical antibiotics to eliminate
enteric carriage through selective digestive tract
decontamination has had mixed results. Some
studies have shown a decrease in respiratory
and urinary tract infections while others have
shown no signiﬁcant difference in overall nosoco-
mial infection rates compared with controls. A
negative result with this approach was increased
colonization with MRSA, enterococci and other
Gram-positive bacteria, as well as with aminogly-
coside-and ﬂuoroquinolone-resistant Gram-nega-
tive organisms. Attempts have been made to
decolonize patients carrying VRE with varying
results. Studies have mainly used bacitracin, alone
[143,144] or in combination with other agents such
as doxycycline [145], and more recently ramopla-
nin [146]. Most of the studies were conducted on a
very small number of patients, were not double-
blind, and used different treatment regimens for
relatively short courses of therapy. The studies to
date indicate a lack of efﬁcacy of bacitracin when
used as a 14-day course. Topical treatment to
removeMRSA carriage has also hadmixed results.
Topical mupirocin has been shown to be effective
in health-care workers, but less so in patients [147].
Systemic antibiotics to remove MRSA carriage
have also had varied success [148].
Vaccination programs
Prevention of disease by vaccination reduces the
overall burden of disease and consequently the
requirement for antimicrobial therapy. There is
also evidence that vaccines may reduce carriage
of resistant organisms. Potentially, this interven-
tion strategy has a very signiﬁcant effect in resis-
tance reduction. The conjugate pneumococcal
vaccine has been demonstrated to be effective in
reducing invasive disease [149] and otitis media
[150] in infants and children. Moreover, in a dou-
ble-blind, randomized, placebo-controlled trial in
500 infants in South Africa, administration of a
nonavalent conjugate vaccine reduced the naso-
pharyngeal carriage of vaccine S. pneumoniae ser-
otypes 6months after vaccination compared with
placebo (18% vs. 36%, respectively); carriage of
nonvaccine serotypes increased. More impor-
tantly, carriage of penicillin-resistant S. pneumo-
niae, regardless of serotype, was signiﬁcantly
reduced compared with placebo (21% vs. 41%,
respectively; P< 0.001), as was carriage of cotri-
moxazole-resistant pneumococci (23% vs. 35%,
respectively; P< 0.003) [151].
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Other developmental vaccines for use against
organisms in which resistance is currently a pro-
blem include those against Mycobacterium tubercu-
losis [152],Helicobacter pylori [153], V. cholerae [154],
and S. typhi [155]. Vaccines under study against
animal pathogens may reduce the requirement
for antimicrobials in food-producing animals
[156–158].
Alternative nonantimicrobial therapies
The use of alternativemodalities to prevent or treat
infectious diseases can potentially reduce the
selective pressure of antimicrobial therapy for
resistance. One option is the use of probiotics or
bacteriotherapy, whereby nonpathogenic organ-
isms are the therapeutic agents [159,160]. For
example, the organisms, Lactobacillus rhamnosus
GG, Biﬁdobacterium spp., and Saccharomyces boular-
dii, have been used with some success in the
treatment of infectious diarrhea in children (parti-
cularly rotavirus-associated diarrhea), antibiotic-
associated diarrhea, and candidal vaginitis. The
mechanisms bywhich probiotic therapy is thought
to work include immunomodulation at the muco-
sal surface, competition with pathogenic organ-
isms, production of antimicrobial agents, and
lactose digestion.
Few studies have researched the role of these
agents in reducing antimicrobial-resistant infec-
tions or colonization. A study comparing cran-
berry–lingonberry juice, Lactobacillus GG drink
and placebo for the prevention of urinary tract
infections in women found only a beneﬁt from the
cranberry–lingonberry juice [161]. A second dou-
ble-blind, placebo-controlled trial in Finland
examined the effect of long-term consumption
(7months) of milk containing L. rhamnosus GG
on gastrointestinal infections and RTIs in 571 chil-
dren attending day-care centers [162]. The results
showed a modest reduction in the incidence and
severity of RTIs and antibiotic use in the study
group. However, statistical signiﬁcance was not
reached. Bacteriologic studies were not per-
formed, so no conclusions can be made regarding
the potential usefulness of Lactobacillus in reducing
carriage of resistant organisms. In a third study, a
mixture of commensal organisms (Streptococcus
sanguinis, Streptococcus mitis, and Streptococcus ora-
lis) was effective in reducing recurrences of otitis
media in children [163]. Children with recurrent
otitis media were randomized to receive either the
streptococcal nasal spray or placebo. During the 3-
month follow-up period, 42% of the study group
did not have a recurrence compared with 22% of
the placebo group (P¼ 0.02). Cultures were per-
formed at the time of inclusion into the study, but
were not repeated and antimicrobial susceptibil-
ities of the isolates were not reported. As the trends
in the last two studies were in the direction of
disease reduction, this is an area for future
research. Importantly, studies should have well-
designed end-points to measure antimicrobial
resistance reduction.
ISSUES SPECIFIC TO
LOW-RESOURCE COUNTRIES
Antimicrobial resistance is as much of a problem
in developing countries as in the developedworld.
However, less is known about the extent of the
problem in developing countries. Furthermore,
the burden of infectious diseases—particularly
RTIs, gastrointestinal infections, tuberculosis, and
malaria—is greater in these regions. Resistance in
M. tuberculosis is a well-recognized problem [164]
and there are some data demonstrating resistance
in shigella, salmonella, campylobacter, V. cholerae
and S. pneumoniae [165]. The interventions for
resistance control outlined above are of relevance
in the industrialized, high-income sections of
developing countries, but these account for only
a fraction of antimicrobial use. In poorer regions,
there are speciﬁc economic, social and behavioral
problems that must be taken into account in any
intervention program.
Two recent reviews provide insight into many
of the problems [166,167]. In brief, health-care
infrastructure is often poorly established in these
countries, with minimal regulatory controls on the
supply of antimicrobials [168]. Antimicrobials are
often prescribed by unskilled practitioners or pur-
chased over the counter by patients [169,170]. Over
the counter availability may not necessarily be the
major contributor to inappropriate use as only a
small proportion of patients self-medicate [171].
Low antibiotic doses, short courses, and poor
compliance all contribute to reduced clinical efﬁ-
cacy and increased selective pressure for resis-
tance. These factors are often the result of
incorrect dosing schedules or poverty, whereby
only a few units of the antimicrobial are purchased
[169]. Counterfeit antimicrobials [172,173], poor
storage conditions, and poor-quality generic
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antibiotics with low bioavailability can also con-
tribute to low dose exposure and selective pres-
sure. In addition, the presence of dispensing
physicians in developing countries may play a
role in the increased use of antimicrobials [174,
175]. Within hospitals, poor hygiene, overcrowd-
ing, lack of resources for infection control, and the
absence of trained infection-control personnel con-
tribute to increased levels of nosocomial infections
and dissemination of resistant organisms.
The use of audit tools to measure the effective-
ness of resistance-control interventions also has
problems speciﬁc to low-resource countries. Resis-
tance surveillance, as a means of identifying pro-
blems and measuring the impact of intervention
programs, is hampered by the lack of trained staff,
the cost of consumablesandequipment, poor access
to standard antimicrobial disks, and the absence of
quality assurance programs [176]. The establish-
ment of sentinel laboratories [177] anddata analysis
using computer programs, such asWHONET [178]
may partially resolve this problem. However, good
antimicrobial-usagedataarehard toobtain indevel-
opingcountries,whichwhencompoundedbya lack
of resources, counterfeit antimicrobials, drug smug-
gling, and limited regulation, the collection of reli-
able data is extremely difﬁcult. Similarly, health
outcome data are very limited.
TheWHOhas recognized that drug accessibility
is of major importance in developing countries.
Through its Action Program on Essential Drugs
(DAP) [179], theWHO is helping these countries to
develop and implement a national drug policy,
which ensures access to essential drugs, rational
use of drugs, and drug quality. Assessment of
the success of the DAP initiative in an individual
country is by a standardized ﬁeld-tested set of basic
drug use indicators [180], as devised by the Inter-
national Network for the Rational Use of Drugs
(INRUD). Antimicrobial use is only a part of the
program and the speciﬁc issue of resistance preven-
tion is not included in the assessment.
It is not surprising, given all the difﬁculties, that
the number of well-monitored resistance-control
interventions with outcome assessment is minimal
in low-resource countries. However, interventions
to improve antimicrobial prescribing practices
have been suggested [181]. A number of papers
were presented at the International Conference on
Improving the Use of Medicines in Chiang Mai,
Thailand, in 1997. Although theywere not directed
toward reducing antimicrobial resistance, most of
the interventions were designed to reduce inap-
propriate antimicrobial use. The outcome mea-
sures chosen were those devised by INRUD
[180]. In one study in Peru, provision of a broad
education program aimed at the community,
carers and physicians resulted in a signiﬁcant
decrease in the percentage of children receiving
antimicrobials for diarrhea [182]. Similarly, educa-
tion of physicians reduced antibiotic use in the
treatment of acute RTIs in Haiti [183] and training
of health-care workers in Vietnam increased the
number of patients receiving appropriate dosing
schedules of antibiotics [184]. Conversely, the
introduction of standard treatment guidelines
alone did not change prescribing practices in
Uganda [185] or Tanzania, where the introduction
was coupled with educational and managerial
strategies [186]. More promisingly, focus group
discussions with drug-selling storekeepers in the
Philippines reduced the sales of penicillin and
amoxicillin [187]. The education of drug retailers
has been in practice in Nepal since 1981, but no
assessment has been made of the effect of this
education program on the appropriateness of pre-
scribing, or the dispensing or storage of antimi-
crobials [188]. There are few reports on regulatory
action (deregistration, relabeling, or restriction)
taken by developing countries to improve drug
usage. However, at the Chiang Mai conference,
regulation to promote generic prescribing was
described. Regulatory action in a number of coun-
tries was reported following the release of WHO
advice on the use of inappropriate therapeutic
agents for diarrhea [189] and, in Nepal, the intro-
duction of a fee structure that discouraged con-
sumer demand has led to a decrease in
antimicrobial prescribing [190].
In summary, implementation of interventions to
limit antimicrobial resistance, particularly in
respiratory and alimentary tract pathogens and
in hospitals, is as important in low-resource coun-
tries as in industrialized ones. Implementation of
these measures is associated with many problems
in low-resource countries. Monitoring the success
of any intervention program will be difﬁcult with-
out ﬁrst establishing the laboratory infrastructure
or augmenting existing facilities to perform resis-
tance surveillance. However, regulatory action to
ensure appropriate access to antimicrobials and to
act against the manufacture of counterfeit and
substandard generic agents should be considered
as a matter of urgency. Assistance from the WHO
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and professional societies could be carefully tar-
geted to maximize the training of local personnel
so that any results can be sustained.
CONCLUSIONS
Many interventions for the control of antimicrobial
resistance are available. Some have been evalu-
ated, to varying degrees, while others are only of
theoretical value at present. It is difﬁcult to prior-
itize these interventions owing to the paucity of
studies that have measured objective end-points,
i.e. reduction in resistance rates and improvement
in health outcomes. Nonetheless, certain general
points can be made. Firstly, 50% of antibiotic con-
sumption in developing countries is in humans
and 50% is in animals [191]. This suggests that
efforts should be made to optimize antibiotic use
in both humans and animals. Human antibiotic
consumption can be categorized further, with 80%
occurring in the community and 20% in hospitals
[192]. Within the community, 80% of antibiotic use
is for the treatment of RTIs [17,18], many of which
do not warrant antibiotic therapy. Therefore, inter-
ventions aimed at community RTI prescribing
should provide maximum beneﬁt in reducing
the overall volume of antimicrobial use.
Efforts should be concentrated at both the pre-
scriber and consumer level. Programs that have
been shown to have the greatest impact in redu-
cing antibiotic use are those that are comprehen-
sive. These programs have targeted prescribers
using a variety of methods, such as: educational
materials; strategies to improve diagnosis; practice
guidelines; personalized, interactive sessions with
feedback on the practice proﬁle; use of delayed
prescriptions; and provision of alternative nonan-
timicrobial prescribing strategies. The best results
are usually obtained when these measures are
combined with consumer education on the self-
limiting nature of many community-acquired
infections (including many RTIs), the role of anti-
biotics in the treatment of these infections, and the
problem of antimicrobial resistance.
With regard to animal use, reductions in resis-
tance have already been seen following regulatory
bans on the use of certain antimicrobials for
growth promotion. Further reductions are possi-
ble, and the prescribers and end users should
beneﬁt from similar educational programs and
interventions, although the evidence for this is
not yet available.
Intervention at the hospital level requires good
infection-control programs to limit the clonal
spread of resistant genetic elements and organ-
isms, as well as modiﬁcation of prescribing prac-
tices. Although the latter is difﬁcult to address,
reducing unnecessary antibiotic usage by effective
practice guidelines will certainly be helpful. It is
also important to understand how to reduce the
selective pressure for resistance arising from clini-
cally warranted antimicrobial therapy. At present,
we do not have sufﬁcient information regarding
the relative selective pressure of different classes
of antimicrobials, nor do we know if strategies
such as antimicrobial restriction or cycling will
reduce the prevalence of resistance. However,
accumulating evidence from pharmacodynamic
studies suggests that optimal dosing of antibiotics
(in terms of dose size, dosage interval, and treat-
ment duration) plays an important role in redu-
cing selective pressure. Improvements in public
health, vaccination programs, and the develop-
ment of new antimicrobials may also help to
reduce the development and spread of resistance.
There are many gaps in our knowledge of the
dynamics of resistance development and spread
and the effectiveness of interventions. Much
research in this area is necessary, particularly in
developing countries. However, our lack of under-
standing should not prevent us from implement-
ing those strategies already shown to be of beneﬁt
and from introducing others with careful monitor-
ing. These interventions must be audited using
the best means possible to determine the ‘best
value for money’. Surveillance of antimicrobial
resistance and use are essential tools that must
be integral to any program. Provision of reliable
surveillance and health outcome data will allow
us to concentrate our efforts and resources on
the most cost-effective approaches to resistance
control.
To initiate and sustain such intervention pro-
grams requires substantial government support
and regulatory control. Many governments and
other health-care organizations are now offering
support, but for a sustainable, effective approach
there must be a strong political will and commit-
ment to succeed.
REFERENCES
1. Austin DJ, Kristinsson KG, Anderson RM. The
relationship between the volume of antimicrobial
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8 (Suppl. 2), 107–128
120 Clinical Microbiology and Infection, Volume 8 Supplement 2, 2002
consumption in human communities and the
frequency of resistance. Proc Natl Acad Sci USA
1999; 96: 1152–6.
2. World Health Organization. ATC Index with Ddds.
Oslo: WHO Collaborating Centre for Drug Statis-
tics Methodology, 1999.
3. Cars O, Molstad S, Melander A. Variation in
antibiotic use in the European Union. Lancet 2001;
357: 1851–3.
4. Felmingham D, Feldman C, Hryniewicz W et al.
Surveillance of resistance in bacteria causing
community-acquired respiratory tract infections.
Clin Microbiol Infect 2002; 8(Suppl. 2): 12–42.
5. Oie Ad Hoc Group on Antimicrobial Resistance.
Guideline No 5. Harmonisation of national anti-
microbial resistance monitoring and surveillance
programmes in animals and in animal derived
food. OIE Sci Tech Rev 2001; 20: 797–870.
6. National Committee for Clinical Laboratory Stan-
dards. Performance Standards for Antimicrobial Sus-
ceptibility Testing. (Suppl.) M100–S11. Wayne, PA:
National Committee for Clinical Laboratory Stan-
dards, 2001.
7. Andrews JM. for the BSAC Working Party on
Susceptibility Testing. BSAC standardized disc
susceptibility testing method. J Antimicrob Che-
mother 2001; 48(Suppl. 1): 43–57.
8. Deutsches Institut fu¨r Normung. Methoden zur
empfindlichkeitspufung von bakteriellen krankheitser-
regern (auber Mycobacterien) gegen chemotherapeuti-
ka. Din 58940. Berlin: Beuth-Verlag GmbH, 2000.
9. Comite´ l’antibiogramme de la Socie´te´ Franc¸aise de
Microbiologie. 1996 Report. Clin Microbiol Infect
1996; 2(Suppl. 2): S1–49.
10. Snell JJS, Brown DFJ. External quality assessment
of antimicrobial susceptibility testing in Europe. J
Antimicrob Chemother 2001; 47: 801–10.
11. Tenover FC, Mohammed MJ, Stelling J et al.
Ability of laboratories to detect emerging anti-
microbial resistance: proficiency testing and qual-
ity control results from the World Health
Organization’s external quality assurance system
for antimicrobial susceptibility testing. J Clin
Microbiol 2001; 39: 241–50.
12. Livermore DM, Macgowan AP, Wale MC. Sur-
veillance of antimicrobial resistance. Centralised
surveys to validate routine data offer a practical
approach. BMJ 1998; 317: 614–15.
13. Livermore DM, Threfall EJ, Reacher MH et al. Are
routine sensitivity test data suitable for the
surveillance of resistance? Resistance rates
amongst Escherichia coli from blood and CSF from
1991 to 1997 as assessed by routine and centralized
testing. J Antimicrob Chemother, 2000; 45: 205–11.
14. Pfaller MA, Acar J, Jones RN, Verhoef J, Turnidge
J, Sader HS. Integration of molecular characteriza-
tion of microorganisms in a global antimicrobial
resistance surveillance program. Clin Infect Dis
2001; 32(Suppl. 2): S156–67.
15. Niederman MS. Impact of antibiotic resistance on
clinical outcomes and the cost of care. Crit Care
Med 2001; 29(Suppl. 4): N114–20.
16. Harris AD, Karchmer TB, Carmeli Y, Samore MH.
Methodological principles of case-control studies
that analyzed risk factors for antibiotic resist-
ance: a systematic review. Clin Infect Dis 2001; 32:
1055–61.
17. Mccaig LF, Hughes JM. Trends in antimicrobial
drug prescribing among office-based physicians in
the United States. JAMA 1995; 273: 214–19.
18. Macfarlane J, Lewis SA, Macfarlane R, Holmes W.
Contemporary use of antibiotics in 1089 adults
presenting with acute lower respiratory tract
illness in general practice in the UK: implications
for developing management guidelines. Respir
Med 1997; 91: 427–34.
19. Mcisaac WJ, Goel V, To T, Low DE. The validity of
a sore throat score in family practice. CMAJ 2000;
163: 811–15.
20. Kolmos HJ, Little P. Controversies in manage-
ment: should general practitioners perform diag-
nostic tests on patients before prescribing
antibiotics? BMJ 1999; 318: 799–802.
21. Grimshaw JM, Russell IT. Effect of clinical guide-
lines on medical practice: a systematic review of
rigorous evaluations. Lancet 1993; 342: 1317–22.
22. Various. Principles of judicious use of antimicro-
bial agents for pediatric upper respiratory tract
infections. Pediatrics 1998; 101(Suppl.): 163–84.
23. Mccaig LF, Besser RE, Hughes JM. Trends in
antimicrobial prescribing rates for children and
adolescents. JAMA 2002; 287: 3096–102.
24. Gonzales R, Bartlett JG, Besser RE et al. Principles
of appropriate antibiotic use for treatment of acute
respiratory tract infections in adults: background,
specific aims, and methods. Ann Intern Med 2001;
134: 479–86.
25. Snow V, Mottur-Pilson C, Gonzales R. Principles
of appropriate antibiotic use for treatment of
nonspecific upper respiratory tract infections in
adults. Ann Intern Med 2001; 134: 487–9.
26. Gonzales R, Bartlett JG, Besser RE, Hickner JM,
Hoffman JR, Sande MA. Principles of appropriate
antibiotic use for treatment of nonspecific upper
respiratory tract infections in adults: background.
Ann Intern Med 2001; 134: 490–4.
27. Snow V, Mottur-Pilson C, Hickner JM. Principles
of appropriate antibiotic use for acute sinusitis in
adults. Ann Intern Med 2001; 134: 495–7.
28. Hickner JM, Bartlett JG, Besser RE, Gonzales R,
Hoffman JR, Sande MA. Principles of appropri-
ate antibiotic use for acute rhinosinusitis in
adults: background. Ann Intern Med 2001; 134:
498–505.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8 (Suppl. 2), 107–128
Christiansen et al Interventions and audit 121
29. Snow V, Mottur-Pilson C, Cooper RJ, Hoffman JR.
Principles of appropriate antibiotic use for acute
pharyngitis in adults. Ann Intern Med 2001; 134:
506–8.
30. Cooper RJ, Hoffman JR, Bartlett JG et al. Principles
of appropriate antibiotic use for acute pharyngitis
in adults: background. Ann Intern Med 2001; 134:
509–17.
31. Snow V, Mottur-Pilson C, Gonzales R. Principles
of appropriate antibiotic use for treatment of acute
bronchitis in adults. Ann Intern Med 2001; 134:
518–20.
32. Gonzales R, Bartlett JG, Besser RE et al. Principles
of appropriate antibiotic use for treatment of
uncomplicated acute bronchitis: background. Ann
Intern Med 2001; 134: 521–9.
33. Niederman MS, Bass JB Jr, Campbell GD et al.
Guidelines for the initial management of adults
with community-acquired pneumonia: diagnosis,
assessment of severity, and initial antimicrobial
therapy. American Thoracic Society. Medical Sec-
tion of the American Lung Association. Am Rev
Respir Dis 1993; 148: 1418–26.
34. Niederman MS, Mandell LA, Anzueto A et al.
Guidelines for the management of adults with
community-acquired pneumonia. Diagnosis, as-
sessment of severity, antimicrobial therapy, and
prevention. Am J Respir Crit Care Med 2001; 163:
1730–54.
35. Bartlett JG, Dowell SF, Mandell LA, File TM Jr,
Musher DM, Fine MJ. Practice guidelines for the
management of community-acquired pneumonia
in adults. Infectious Diseases Society of America.
Clin Infect Dis 2000; 31: 347–82.
36. Mandell LA, Marrie TJ, Grossman RF, Chow AW,
Hyland RH. Canadian guidelines for the initial
management of community-acquired pneumonia:
an evidence-based update by the Canadian In-
fectious Diseases Society and the Canadian Thor-
acic Society. The Canadian Community-Acquired
Pneumonia Working Group. Clin Infect Dis 2000;
31: 383–421.
37. Huchon G, Woodhead M, the European Study on
Community Acquired Pneumonia Committee.
Management of adult community-acquired lower
respiratory tract infection. Eur Respir Rev 1998; 8:
391–426.
38. British Thoracic Society Standards of Care
Committee. British Thoracic Society guidelines
for the management of community-acquired pneu-
monia in childhood. Thorax 2002; 57(Suppl. 1):
i1–24.
39. Gleason PP, Kapoor WN, Stone RA et al. Medical
outcomes and antimicrobial costs with the use of
the American Thoracic Society guidelines for
outpatients with community-acquired pneumonia.
JAMA 1997; 278: 32–9.
40. Barwitz HJ. Sore throat consultation—what is the
value of a treatment guideline? MMW Fortschr
Med 1999; 141: 32–6.
41. Pestotnik SL, Classen DC, Evans S, Burke
JP. Implementing antibiotic practice guidelines
through computer-assisted decision support: clin-
ical and financial outcomes. Ann Intern Med 1996;
124: 884–90.
42. Evans RS, Pestotnik SL, Classen DC et al. A
computer-assisted management program for anti-
biotics and other antiinfective agents. N Engl J Med
1998; 338: 232–8.
43. Mainous AG, 3rd Hueston WJ, Love MM, Evans
ME, Finger R. An evaluation of statewide strate-
gies to reduce antibiotic overuse. Fam Med 2000;
32: 22–9.
44. O’Connell DL, Henry D, Tomlins R. Randomised
controlled trial of effect of feedback on general
practitioners’ prescribing in Australia. BMJ 1999;
318: 507–11.
45. Hux JE, Melady MP, Deboer D. Confidential
prescriber feedback and education to improve
antibiotic use in primary care: a controlled trial.
CMAJ 1999; 161: 388–92.
46. Zwar N, Wolk J, Gordon J, Sanson-Fisher R, Kehoe
L. Influencing antibiotic prescribing in general
practice: a trial of prescriber feedback and man-
agement guidelines. Fam Pract 1999; 16: 495–500.
47. Ekedahl A, Andersson SI, Hovelius B, Molstad S,
Liedholm H, Melander A. Drug prescription
attitudes and behaviour of general practitioners.
Effects of a problem-oriented educational pro-
gramme. Eur J Clin Pharmacol 1995; 47: 381–7.
48. Munck AP, Gahrn-Hansen B, Sogaard P, Sogaard
J. Long-lasting improvement in general practi-
tioners’ prescribing of antibiotics by means of
medical audit. Scand J Prim Health Care 1999; 17:
185–90.
49. De Santis G, Harvey KJ, Howard D, Mashford ML,
Moulds RF. Improving the quality of antibiotic
prescription patterns in general practice. The role
of educational intervention. Med J Aust 1994; 160:
502–5.
50. Stewart J, Pilla J, Dunn L. Pilot study for
appropriate anti-infective community therapy.
Effect of a guideline-based strategy to optimize
use of antibiotics. Can Fam Physician 2000; 46:
851–9.
51. Gonzales R, Steiner JF, Lum A, Barrett PH Jr.
Decreasing antibiotic use in ambulatory practice:
impact of multidimensional intervention on the
treatment of uncomplicated acute bronchitis in
adults. JAMA 1999; 281: 1512–19.
52. Solomon DH, Van Houten L, Glynn RJ et al.
Academic detailing to improve use of broad-
spectrum antibiotics at an academic medical
center. Arch Intern Med 2001; 161: 1897–902.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8 (Suppl. 2), 107–128
122 Clinical Microbiology and Infection, Volume 8 Supplement 2, 2002
53. Cates C. An evidence based approach to reducing
antibiotic use in children with acute otitis media:
controlled before and after study. BMJ 1999; 318:
715–16.
54. Little P, Gould C, Williamson I, Moore M, Warner
G, Dunleavy J. Pragmatic randomized controlled
trial of two prescribing strategies for childhood
acute otitis media. BMJ 2001; 322: 336–42.
55. Couchman GR, Rascoe TG, Forjuoh SN. Back-up
antibiotic prescriptions for common respiratory
symptoms. Patient satisfaction and fill rates. J Fam
Pract 2000; 49: 907–13.
56. Hulscher ME, Wensing M, van Der Weijden T,
Grol R. Interventions to implement prevention in
primary care. Cochrane Database Syst Rev 2001; 1:
CD000362.
57. Gross PA, Pujat D. Implementing practice guide-
lines for appropriate antimicrobial usage. A
systematic review. Med Care 2001; 39(8 Suppl. 2):
II55–69.
58. Trepka MJ, Belongia EA, Chyou PH, Davis JP,
Schwartz B. The effect of a community interven-
tion trial on parental knowledge and awareness of
antibiotic resistance and appropriate antibiotic use
in children. Pediatrics 2001; 107: E6.
59. Bauraind I, Vanden Bremt I, Bogaert M et al.
Evaluation of the impact of a public campaign for
a more rational use of antibiotics in Belgium.
Presented at the 41st Interscience Conference on
Antimicrobial Agents and Chemotherapy 2001;
Abstract LB–9.
60. The European Agency for the Evaluation of
Medicinal Products. Notes for the Guidance on the
Pharmacodynamics Section of the SPC for Anti-
bacterial Medicinal Products, CPMP/EWP/520/96.
London: EMEA, 1997.
61. The European Agency for the Evaluation of
Medicinal Products. Points to Consider on Pharma-
cokinetics and Pharmacodynamics in the Development
of Antibacterial Medicinal Products, CPMP/EWP/
2655/99. London: EMEA, 2000.
62. Stephenson J. Icelandic researchers are showing
the way to bring down rates of antibiotic-resistant
bacteria. JAMA 1996; 275: 175.
63. Turnidge JD, Bell JM, Collignon PJ. Rapidly
emerging antimicrobial resistances in Streptococcus
pneumoniae in Australia. Pneumococcal Study
Group. Med J Aust 1999; 170: 152–5.
64. Bell JM, Turnidge JD, and the SENTRY Western
Pacific plus participants. Emerging resistance to
fluoroquinolones: results from the SENTRY sur-
veillance program for Asia, Australia, and South
Africa. Presented at the 39th Interscience Con-
ference on Antimicrobial Agents and Chemother-
apy, 1999; Abstract C2–2258.
65. Commonwealth Department of Health and Aged
Care. Australian Statistics on Medicines 1998.
Retrieved on 25 June 2002 from http://www.
health.gov.au/pbs/pubs/pdf/asm98.pdf.
66. van den Bogaard AE, Stobberingh EE. Epidemiol-
ogy of resistance to antibiotics. Links between
animals and humans. Int J Antimicrob Agents 2000;
14: 327–35.
67. Wegener HC, Aarestrup FM, Jensen LB, Hammer-
um AM, Bager F. Use of antimicrobial growth
promoters in food animals and Enterococcus
faecium resistance to therapeutic antimicrobial
drugs in Europe. Emerg Infect Dis 1999; 5: 329–35.
68. Klare I, Badstubner D, Konstabel C, Bohme G,
Claus H, Witte W. Decreased incidence of VanA-
type vancomycin resistant enterococci isolated
from poultry meat and from fecal samples of
humans in the community after discontinuation of
avoparcin usage in animal husbandry. Microb
Drug Resist 1999; 5: 45–52.
69. Pantosti A, Del Grosso M, Tagliabue S, Macri A,
Caprioli A. Decrease of vancomycin-resistant
enterococci in poultry meat after avoparcin ban.
Lancet 1999; 354: 741–2.
70. van Den Bogaard AE, London N, Stobberingh EE.
Antimicrobial resistance in pig faecal samples
from The Netherlands (five abattoirs) and Sweden.
J Antimicrob Chemother 2000; 45: 663–71.
71. Wierup M. The control of microbial diseases in
animals: alternatives to the use of antibiotics. Int J
Antimicrob Agents 2000; 14: 315–19.
72. The European Agency for the Evaluation of
Medicinal Products. Antibiotic Resistance in the
European Union Associated with Therapeutic Use of
Veterinary Medicines, CVMP/342/99, Chapter 11.
London: EMEA, 1999.
73. Zulkifli I, Abdullah N, Azrin NM, Ho YW. Growth
performance and immune response of two com-
mercial broiler strains fed diets containing Lacto-
bacillus cultures and oxytetracycline under heat
stress conditions. Br Poult Sci 2000; 41: 593–7.
74. Verschuere L, Rombaut G, Sorgeloos P, Verstraete
W. Probiotic bacteria as biological control agents
in aquaculture. Microbiol Mol Biol Rev 2000; 64:
655–71.
75. Zhao T, Doyle MP, Harmon BG, Brown CA,
Mueller PO, Parks AH. Reduction of carriage of
enterohemorrhagic Escherichia coli O157: H7 in
cattle by inoculation with probiotic bacteria. J Clin
Microbiol 1998; 36: 641–7.
76. Morishita TY, Aye PP, Harr BS, Cobb CW, Clifford
JR. Evaluation of an avian-specific probiotic to
reduce the colonization and shedding of Campylo-
bacter jejuni in broilers. Avian Dis 1997; 41: 850–5.
77. World Health Organization.WHO Global Principles
for the Containment of Antimicrobial Resistance in
Animals Intended for Food. Retrieved on 25 June
2002 from http://who.int/emc/diseases/zoo/
who_global_principles.html.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8 (Suppl. 2), 107–128
Christiansen et al Interventions and audit 123
78. Aliabadi FS, Lees P. Antibiotic treatment for
animals: effect on bacterial population and dosage
regimen optimization. Int J Antimicrob Agents 2000;
14: 307–13.
79. Craig WA. Pharmacokinetic/pharmacodynamic
parameters: rationale for antibacterial dosing of
mice and men. Clin Infect Dis 1998; 26: 1–12.
80. Andes D. Pharmacokinetic and pharmacodynamic
properties of antimicrobials in the therapy of
respiratory tract infections. Curr Opin Infect Dis
2001; 14: 165–72.
81. Blaser J, Stone BB, Groner MC, Zinner SH.
Comparative study with enoxacin and netilmicin
in a pharmacodynamic model to determine im-
portance of antibiotic peak concentration to MIC
for bactericidal activity and emergence of resis-
tance. Antimicrob Agents Chemother 1987; 31:
1054–60.
82. Drusano GL, Johnson DE, Rosen M, Standiford
HC. Pharmacodynamics of a fluoroquinolone
antimicrobial agent in a neutropenic rat model of
Pseudomonas sepsis. Antimicrob Agents Chemother
1993; 37: 483–90.
83. Marchbanks CR, Mckiel JR, Gilbert DH et al. Dose
ranging and fractionation of intravenous cipro-
floxacin against Pseudomonas aeruginosa and Sta-
phylococcus aureus in an in vitro model of infection.
Antimicrob Agents Chemother 1993; 37: 1756–63.
84. Madaras-Kelly KJ, Ostergaard BE, Hovde LB,
Rotschafer JC. Twenty-four-hour area under the
concentration–time curve/MIC ratio as a generic
predictor of fluoroquinolone antimicrobial effect
by using three strains of Pseudomonas aeruginosa
and an in vitro pharmacodynamic model. Anti-
microb Agents Chemother 1996; 40: 627–32.
85. Martinez JL, Baquero F. Mutation frequencies and
antibiotic resistance. Antimicrob Agents Chemother
2000; 44: 1771–7.
86. Blondeau JM, Zhao X, Hansen G, Drlica K. Mutant
prevention concentrations of fluoroquinolones for
clinical isolates of Streptococcus pneumoniae. Anti-
microb Agents Chemother 2001; 45: 433–8.
87. Thomas JK, Forrest A, Bhavnani SM et al.
Pharmacodynamic evaluation of factors associated
with the development of bacterial resistance in
acutely ill patients during therapy. Antimicrob
Agents Chemother 1998; 42: 521–7.
88. Arason VA, Kristinsson KG, Sigurdsson JA,
Stefansdottir G, Molstad S, Gudmundsson S. Do
antimicrobials increase the carriage rate of peni-
cillin resistant pneumococci in children? Cross
sectional prevalence study. BMJ 1996; 313: 387–91.
89. Dagan R, Leibovitz E, Greenberg D, Yagupsky P,
Fliss DM, Leiberman A. Dynamics of pneumococ-
cal nasopharyngeal colonization during the first
days of antibiotic treatment in pediatric patients.
Pediatr Infect Dis J 1998; 17: 880–5.
90. Dagan R, Klugman KP, Craig WA, Baquero F.
Evidence to support the rationale that bacterial
eradication in respiratory tract infection is an
important aim of antimicrobial therapy. J Anti-
microb Chemother 2001; 47: 129–40.
91. Schrag SJ, Beall B, Dowell SF. Limiting the spread
of resistant pneumococci: biological and epide-
miologic evidence for the effectiveness of alter-
native interventions. Clin Microbiol Rev 2000; 13:
588–601.
92. Guillemot D, Carbon C, Balkau B et al. Low
dosage and long treatment duration of beta-
lactam: risk factors for carriage of penicillin-
resistant Streptococcus pneumoniae. JAMA 1998;
279: 365–70.
93. Schrag SJ, Pena C, Fernandez J et al. Effect of short-
course, high-dose amoxicillin therapy on resistant
pneumococcal carriage: a randomized trial. JAMA
2001; 286: 49–56.
94. Ghaffar FA, Katz K, Miniz LS et al. Effect of
amoxicillin–clavulanate 14:1 vs azithromycin on
nasopharyngeal carriage carriage and resistant S.
pneumoniae. Clin Infect Dis 2000; 31: 230.
95. Galluppi GR, Rogge MC, Roskos LK et al.
Integration of pharmacokinetic and pharmacody-
namic studies in the discovery, development, and
review of protein therapeutic agents: a conference
report. Clin Pharmacol Ther 2001; 69: 387–99.
96. Rice LB, Willey SH, Papanicolaou GA et al.
Outbreak of ceftazidime resistance caused by
extended-spectrum beta-lactamases at a Massa-
chusetts chronic-care facility. Antimicrob Agents
Chemother 1990; 34: 2193–9.
97. Enne VI, Livermore DM, Stephens P, Hall LM.
Persistence of sulphonamide resistance in Escher-
ichia coli in the UK despite national prescribing
restriction. Lancet 2001; 357: 1325–8.
98. Chiew YF, Yeo SF, Hall LM, Livermore DM. Can
susceptibility to an antimicrobial be restored by
halting its use? The case of streptomycin versus
Enterobacteriaceae. J Antimicrob Chemother 1998; 41:
247–51.
99. White AC Jr, Atmar RL, Wilson J, Cate TR, Stager
CE, Greenberg SB. Effects of requiring prior
authorization for selected antimicrobials: expendi-
tures, susceptibilities and clinical outcomes. Clin
Infect Dis 1997; 25: 230–9.
100. Quale J, Landman D, Saurina G, Atwood E, Ditore
V, Patel K. Manipulation of a hospital antimicro-
bial formulary to control an outbreak of vanco-
mycin-resistant enterococci. Clin Infect Dis 1996;
23: 1020–5.
101. Bradley SJ, Wilson AL, Allen MC, Sher HA,
Goldstone AH, Scott GM. The control of hyperen-
demic glycopeptide-resistant Enterococcus spp. on
a haematology unit by changing antibiotic usage. J
Antimicrob Chemother 1999; 43: 261–6.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8 (Suppl. 2), 107–128
124 Clinical Microbiology and Infection, Volume 8 Supplement 2, 2002
102. Rahal JJ, Urban C, Horn D et al. Class restriction of
cephalosporin use to control total cephalosprin
resistance in nosocomial Klebsiella. JAMA 1998;
280: 1233–7.
103. Pena C, Pujol M, Ardanuy C et al. Epidemiology
and successful control of a large outbreak due to
Klebsiella pneumoniae producing extended-spec-
trum beta-lactamases. Antimicrob Agents Chemother
1998; 42: 53–8.
104. Pearman J, Perry P, Lee R, Mitchell D. Restriction of
third-generation cephalosporins plus infection con-
trol measures ended recurrent outbreaks of multi-
resistant Acinetobacter baumannii in an Australian
hospital. Aust Infect Control 1999; 4: 16–24.
105. Gerding DN, Larson TA, Hughes RA, Weiler M,
Shanholtzer C, Peterson LR. Aminoglycoside
resistance and aminoglycoside usage: ten years
of experience in one hospital. Antimicrob Agents
Chemother 1991; 35: 1284–90.
106. Gerding DN. Antimicrobial cycling: lessons
learned from the aminoglycoside experience. Infect
Control Hosp Epidemiol 2000; 21(Suppl. 1): S12–17.
107. John JF Jr. Antibiotic cycling: is it ready for prime
time? Infect Control Hosp Epidemiol 2000; 21: 9–11.
108. Kollef MH. Is there a role for antibiotic cycling in
the intensive care unit? Crit Care Med 2001;
29(Suppl. 4): N135–42.
109. Kollef MH, Vlasnik J, Sharpless L, Pasque C,
Murphy D, Fraser V. Scheduled change of anti-
biotic classes: a strategy to decrease the incidence
of ventilator-associated pneumonia. Am J Respir
Crit Care Med 1997; 156: 1040–8.
110. Kollef MH, Ward S, Sherman G et al. Inadequate
treatment of nosocomial infections is associated
with certain empiric antibiotic choices. Crit Care
Med 2000; 28: 3456–64.
111. Gruson D, Hilbert G, Vargas F et al. Rotation and
restricted use of antibiotics in a medical intensive
care unit. Impact on the incidence of ventilator-
associated pneumonia caused by antibiotic-resis-
tant gram-negative bacteria. Am J Respir Crit Care
Med 2000; 162: 837–43.
112. Dominguez EA, Smith TL, Reed E, Sanders CC,
Sanders WE Jr. A pilot study of antibiotic cycling
in a hematology–oncology unit. Infect Control Hosp
Epidemiol 2000; 21(Suppl. 1): S4–8.
113. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating
treatment protocols to prevent antibiotic resis-
tance. Proc Natl Acad Sci USA 1997; 94: 12106–11.
114. John JF, Rice LB. The microbial genetics of
antibiotic cycling. Infect Control Hosp Epidemiol
2000; 21 (Suppl. 1): S22–31.
115. Mcgowan JE Jr. Strategies for study of the role of
cycling on antimicrobial use and resistance. Infect
Control Hosp Epidemiol 2000; 21(1 Suppl.): S36–43.
116. Melander E, Molstad S, Persson K, Hansson HB,
Soderstrom M, Ekdahl K. Previous antibiotic
consumption and other risk factors for carriage
of penicillin-resistant Streptococcus pneumoniae in
children. Eur J Clin Microbiol Infect Dis 1998; 17:
834–8.
117. Dagan R, Melamed R, Muallem M, Piglansky L,
Yagupsky P. Nasopharyngeal colonization in
southern Israel with antibiotic-resistant pneumo-
cocci during the first 2 years of life: relation to
serotypes likely to be included in pneumococcal
conjugate vaccines. J Infect Dis 1996; 174: 1352–5.
118. Christenson B, Sylvan SP, Noreen B. Drug-
resistant Streptococcus pneumoniae in daycare cen-
tres in Stockholm County. J Infect 1998; 37: 9–14.
119. Reichler MR, Allphin AA, Breiman RF et al. The
spread of multiply resistant Streptococcus pneumo-
niae at a day care center in Ohio. J Infect Dis 1992;
166: 1346–53.
120. Leach AJ, Shelby-James T, Mayo M, Gratten M,
Mathews JD. Report of a multidrug resistant clone
of Streptococcus pneumoniae (MRSPN) in aboriginal
infants in the Northern Territory. Commun Dis
Intell 1995; 19: 134–7.
121. Lipsitch M. Measuring and interpreting associa-
tions between antibiotic use and penicillin resis-
tance in Streptococcus pneumoniae. Clin Infect Dis
2001; 32: 1044–54.
122. Dagan R, Leibovitz E, Cheletz G, Leiberman A,
Porat N. Antibiotic treatment in acute otitis media
promotes superinfection with resistant Streptococ-
cus pneumoniae carried before initiation of treat-
ment. J Infect Dis 2001; 183: 880–6.
123. Ekdahl K, Cars O. Role of communicable disease
control measures in affecting the spread of
resistant pneumococci: the Swedish model. Clin
Microbiol Infect 1999; 5(Suppl. 4): S48–54.
124. Rowe B, Ward LR, Threlfall EJ. Multidrug-resis-
tant Salmonella typhi: a worldwide epidemic. Clin
Infect Dis 1997; 24(Suppl. 1): S106–9.
125. Coppo A, Colombo M, Pazzani C et al. Vibrio
cholerae in the horn of Africa: epidemiology,
plasmids, tetracycline resistance gene amplifica-
tion, and comparison between O1 and non-O1
strains. Am J Trop Med Hyg 1995; 53: 351–9.
126. Threlfall EJ, Ward LR, Skinner JA, Smith HR,
Lacey S. Ciprofloxacin-resistant Salmonella typhi
and treatment failure. Lancet 1999; 353: 1590–9.
127. Garg P, Chakraborty S, Basu I et al. Expanding
multiple antibiotic resistance among clinical
strains of Vibrio cholerae isolated from 1992 to
1997 in Calcutta. India Epidemiol Infect 2000; 124:
393–9.
128. Seas C, Alarcon M, Aragon JC et al. Surveillance of
bacterial pathogens associated with acute diarrhea
in Lima, Peru. Int J Infect Dis 2000; 4: 96–9.
129. Olsen SJ, Debess EE, Mcgivern TE et al. A nos-
ocomial outbreak of fluoroquinolone-resistant sal-
monella infection. N Engl J Med 2001; 344: 1572–9.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8 (Suppl. 2), 107–128
Christiansen et al Interventions and audit 125
130. O’Brien FG, Pearman JW, Gracey M, Riley TV,
Grubb WB. Community strain of methicillin-
resistant Staphylococcus aureus involved in a
hospital outbreak. J Clin Microbiol 1999; 37: 2858–
62.
131. Semmelweis IF. The Etiology, Concept and Prophy-
laxis of Childbed Fever Madison: University of
Wisconsin Press, 1983.
132. Pittet D, Mourouga P, Perneger TU. Compliance
with handwashing in a teaching hospital. Ann
Intern Med 1999; 130: 126–30.
133. Weinstein RA. Controlling antimicrobial resis-
tance in hospitals: infection control and use of
antibiotics. Emerg Infect Dis 2001; 7: 188–92.
134. Conly JM, Hill S, Ross J, Lertzman J, Louie TJ.
Handwashing practices in an intensive care unit:
the effects of an educational program and its
relationship to infection rates. Am J Infect Control
1989; 17: 330–9.
135. Bischoff WE, Reynolds TM, Sessler CN, Edmond
MB, Wenzel RP. Handwashing compliance by
health care workers: the impact of introducing an
accessible, alcohol-based hand antiseptic. Arch
Intern Med 2000; 160: 1017–21.
136. Bonten MJ, Slaughter S, Ambergen AW et al. The
role of ‘colonization pressure’ in the spread of
vancomycin-resistant enterococci: an important
infection control variable. Arch Intern Med 1998;
158: 1127–32.
137. Austin DJ, Bonten MJ, Weinstein RA, Slaughter S,
Anderson RM. Vancomycin-resistant enterococci
in intensive-care hospital settings: transmission
dynamics, persistence, and the impact of infection
control programs. Proc Natl Acad Sci USA 1999; 96:
6908–13.
138. Mcmanus AT, Mason AD Jr, Mcmanus WF, Pruitt
BA Jr. A decade of reduced gram-negative infec-
tions and mortality associated with improved
isolation of burned patients. Arch Surg 1994; 129:
1306–9.
139. Lingnau W, Allerberger F. Control of an outbreak
of methicillin-resistant Staphylococcus aureus
(MRSA) by hygienic measures in a general
intensive care unit. Infection 1994; 22(Suppl. 2):
S135–9.
140. Jernigan JA, Titus MG, Groschel DH, Getchell-
White S, Farr BM. Effectiveness of contact isolation
during a hospital outbreak of methicillin-resistant
Staphylococcus aureus. Am J Epidemiol 1996; 143:
496–504.
141. Johnson S, Gerding DN, Olson MM et al. Prospec-
tive, controlled study of vinyl glove use to
interrupt Clostridium difficile nosocomial transmis-
sion. Am J Med 1990; 88: 137–40.
142. Warren DK, Fraser VJ. Infection control measures
to limit antimicrobial resistance. Crit Care Med
2001; 29 (Suppl. 4): N128–34.
143. O’Donovan CA, Fan-Havard P, Tecson-Tumang
FT, Smith SM, Eng RHK. Enteric eradication of
vancomycin-resistant Enterococcus faecium with
oral bacitracin. Diagn Microbiol Infect Dis 1994; 18:
105–9.
144. Chia JKS, Nakata MM, Park SS, Lewis RP, Mckee
B. Use of bacitracin therapy for infection due to
vancomycin-resistant Enterococcus faecium. Clin
Infect Dis 1995; 21: 1520.
145. Weinstein MR, Dedier H, Brunton J, Campbell I,
Conly JM. Lack of efficacy of oral bacitracin plus
doxycycline for the eradication of stool colonisa-
tion with vancomycin-resistant Enterococcus fae-
cium. Clin Infect Dis 1999; 29: 361–6.
146. Wong MT, Kauffman CA, Standiford HC et al.
Effective suppression of vancomycin-resistant En-
terococcus species in asymptomatic gastrointestinal
carriers by a novel glycolipodepsipeptide, ramo-
planin. Clin Infect Dis 2001; 33: 1476–82.
147. Boyce JM. MRSA patients: proven methods to treat
colonization and infection. J Hosp Infect 2001;
48(Suppl. A): S9–S14.
148. Whitby M. Fusidic acid in the treatment of
methicillin-resistant Staphylococcus aureus. Int J
Antimicrob Agents 1999; 12(Suppl. 2): S67–71.
149. Black S, Shinefield H, Fireman B et al. Efficacy,
safety and immunogenicity of heptavalent pneu-
mococcal conjugate vaccine in children. Northern
California Kaiser Permanente Vaccine Study Center
Group. Pediatr Infect Dis J 2000; 19: 187–95.
150. Eskola J, Kilpi T, Palmu A et al. Efficacy of a
pneumococcal conjugate vaccine against acute
otitis media. N Engl J Med 2001; 344: 403–9.
151. Mbelle N, Huebner RE, Wasas AD, Kimura A,
Chang I, Klugman KP. Immunogenicity and
impact on nasopharyngeal carriage of a nonava-
lent pneumococcal conjugate vaccine. J Infect Dis
1999; 180: 1171–6.
152. Young DB. Current tuberculosis vaccine develop-
ment. Clin Infect Dis 2000; 30(Suppl. 3): S254–6.
153. Vyas SP, Sihorkar V. Exploring novel vaccines
againstHelicobacter pylori: protective and therapeutic
immunization. J Clin Pharm Ther 1999; 24: 259–72.
154. Coster TS, Killeen KP, Waldor MK et al. Safety,
immunogenicity, and efficacy of live attenuated
Vibrio cholerae O139 vaccine prototype. Lancet 1995;
345: 949–52.
155. Lin FY, Ho VA, Khiem HB et al. The efficacy of a
Salmonella typhi Vi conjugate vaccine in two-to-
five-year-old children. N Engl J Med 2001; 344:
1263–9.
156. Zhang-Barber L, Turner AK, Barrow PA. Vaccina-
tion for control of Salmonella in poultry. Vaccine
1999; 17: 2538–45.
157. Yancey RJ Jr. Vaccines and diagnostic methods for
bovine mastitis: fact and fiction. Adv Vet Med 1999;
41: 257–73.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8 (Suppl. 2), 107–128
126 Clinical Microbiology and Infection, Volume 8 Supplement 2, 2002
158. Vinitnantharat S, Gravningen K, Greger E. Fish
vaccines. Adv Vet Med 1999; 41: 539–50.
159. Alvarez-Olmos MI, Oberhelman RA. Probiotic
agents and infectious diseases: a modern perspec-
tive on a traditional therapy. Clin Infect Dis 2001;
32: 1567–76.
160. Huovinen P. Bacteriotherapy: the time has come.
BMJ 2001; 323: 353–4.
161. Kontiokari T, Sundqvist K, Nuutinen M, Pokka T,
Koskela M, Uhari M. Randomised trial of cran-
berry-lingonberry juice and Lactobacillus GG drink
for the prevention of urinary tract infections in
women. BMJ 2001; 322: 1571.
162. Hatakka K, Savilahti E, Ponka A et al. Effect of
long term consumption of probiotic milk on
infections in children attending day care centres:
double blind, randomised trial. BMJ 2001; 322:
1327–9.
163. Roos K, Hakansson EG, Holm S. Effect of
recolonisation with ‘interfering’ alpha streptococci
on recurrences of acute and secretory otitis media
in children: randomised placebo controlled trial.
BMJ 2001; 322: 1–4.
164. Espinal MA, Laszlo A, Simonsen L et al. Global
trends in resistance to antituberculosis drugs.
World Health Organization–International Union
against Tuberculosis and Lung Disease Work-
ing Group on Anti-Tuberculosis Drug Resist-
ance Surveillance. N Engl J Med 2001; 344:
1294–303.
165. Hart CA, Kariuki S. Antimicrobial resistance in
developing countries. BMJ 1998; 317: 647–50.
166. Okeke IN, Lamikanra A, Edelman R. Socioeco-
nomic and behavioral factors leading to acquired
bacterial resistance to antibiotics in developing
countries. Emerg Infect Dis 1999; 5: 18–27.
167. Isturiz RE, Carbon C. Antibiotic use in developing
countries. Infect Control Hosp Epidemiol 2000; 21:
394–7.
168. Bapna JS, Tripathi CD, Tekur U. Drug utilisation
patterns in the Third World. Pharmacoeconomics
1996; 9: 286–94.
169. Lansang MA, Lucas-Aquino R, Tupasi TE et al.
Purchase of antibiotics without prescription in
Manila, the Philippines. Inappropriate choices and
doses. J Clin Epidemiol 1990; 43: 61–7.
170. Siringi S. Over-the-counter sale of antimalaria
drugs stalls Kenyan disease strategy. Lancet 2001;
357: 1862.
171. Sturm AW, van der Pol R, Smits AJ et al. Over-
the-counter availability of antimicrobial agents,
self-medication and patterns of resistance in
Karachi, Pakistan. J Antimicrob Chemother 1997;
39: 543–7.
172. Chatterjee P. India’s trade in fake drugs—bring-
ing the counterfeiters to book. Lancet 2001; 357:
1776.
173. Newton P, Proux S, Green M et al. Fake
artesunate in southeast Asia. Lancet 2001; 357:
1948–50.
174. Favre I. Strict separation between prescription and
delivery tasks: a strategy to improve medication use
and distribution in Thailand. Presented at the
International Conference on Improving the Use
of Medicines Chiang Mai, Thailand, April 1997.
Retrieved on 25 June 2002 from http://www.
who.ch/dap-icium/posters/4b1_text.html.
175. Trap B. Practices by dispensing doctors related to
rational drug use and health economics. Presented at
the International Conference on Improving the
Use of Medicines Chiang Mai, Thailand, April
1997. Retrieved on 25 June 2002 from. http://
www.who.ch/dap-icium/posters/4b4_fin.html.
176. Brown RC. Antibiotic sensitivity testing for infec-
tions in developing countries: lacking the basics.
JAMA 1996; 276: 952–3.
177. Archibald LK, Reller LB. Clinical microbiology in
developing countries. Emerg Infect Dis 2001; 7:
302–5.
178. Stelling JM, O’Brien TF. Surveillance of antimicro-
bial resistance: the WHONET program. Clin Infect
Dis 1997; 24(Suppl. 1): S157–68.
179. World Health Organization. Guide for the Formula-
tion and Implementation of a National Drug Policy and
a National Pharmaceutical Masterplan. Annex to
documents WHO/DAP93.9; WHO/DAP/93.11;
WHO/DAP/93.12. Geneva: WHO, 1996.
180. Hogerzeil HV, Bimo Ross-Degnan D, Laing RO
et al. Field tests for rational drug use in twelve
developing countries. Lancet 1993; 342: 1408–10.
181. Laing RO, Hogerzeil HV, Ross-Degnan D. Ten
recommendations to improve use of medicines in
developing countries. Health Policy Plan 2001; 16:
13–20.
182. Paredes P, Yeager BAC, Montalvo J, Arana A.
Intervention trial to decrease unjustified use of
pharmaceutical drugs in the treatment of childhood
diarrhea, Lima, Peru. Presented at the International
Conference on Improving the Use of Medicines
Chiang Mai, Thailand, April 1997. Retrieved on 25
June 2002 from http://www.who.ch/dap-icium/
posters/3A2_text.html.
183. Aupont O. Reducing multiple antibiotics in treatment
of acute respiratory infections (ARI): a planned
intervention in Haiti. Presented at the International
Conference on Improving the Use of Medicines
Chiang Mai, Thailand, April 1997. Retrieved on 25
June 2002 from http://www.who.ch/dap-icium/
posters/2P17_txt.html.
184. Chalker J, Phuong NK. Combating the growth of
resistance to antibiotics. Antibiotic dose as an indicator
for rational drug use. Presented at the International
Conference on Improving the Use of Medicines
Chiang Mai, Thailand, April 1997. Retrieved on 25
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8 (Suppl. 2), 107–128
Christiansen et al Interventions and audit 127
June 2002 from http://www.who.ch/dap-icium/
posters/2E1_txtf.html.
185. Kafuko JM, Zirabamuzaale C, Bagenda D. Rational
drug use in rural health units of Uganda. Effect of
National Standard Treatment Guidelines on Rational
Drug Use. Presented at the International Confer-
ence on Improving the Use of Medicines Chiang
Mai, Thailand, April 1997. Retrieved on 25 June
2002 from http://www.who.ch/dap-icium/pos-
ters/2f3_text.html.
186. Wiedenmayer K, Mtasiwa D, Majapa Z, Lorenz N.
Impact of pilot intervention (Standard Treatment
Guidelines, training) on prescribing patterns in Dar
es Salaam. Presented at the International Confer-
ence on Improving the Use of Medicines Chiang
Mai, Thailand, April 1997. Retrieved on 25 June
2002 from http://www.who.ch/dap-icium/pos-
ters/2f4_text.html.
187. Sia IC, Valerin J. The effect of an intervention on
the drug selling behavior of sarisari (variety) store
keepers in some villages in the Philippines. Presented
at the International Conference on Improving
the Use of Medicines Chiang Mai, Thailand, April
1997. Retrieved on 25 June 2002 from http://
www.who.ch/dap-icium/posters/3C4_txtf.html.
188. Kafle KK, Gartoulla RP, Pradhan YM, Shrestha AD,
Karkee SB, Quick JD. Drug retailer training: experi-
ences from Nepal. Soc Sci Med 1992; 35: 1015–25.
189. Haak H, Cleason M. Regulatory actions to enhance
appropriate drug use: the case of drugs. Presented at
the International Conference on Improving the
Use of Medicines Chiang Mai, Thailand, April
1997. Retrieved on 25 June 2002 from http://
www.who.ch/dap-icium/posters/4A1_text.html.
190. Hollaway KA, Gautam BR. The effects of different
charging mechanisms on rational drug use in eastern
rural Nepal. Presented at the International Con-
ference on Improving the Use of Medicines
Chiang Mai, Thailand, April 1997. Retrieved on
25 June 2002 from http://www.who.ch/dap-
icium/posters/4e2_text.html.
191. FEDESA. Press release on the European UnionCon-
ference. The Microbial Threat, Copenhagen, 1998.
192. Wise R, Hart T, Cars O et al. Antimicrobial
resistance is a major threat to public health. BMJ
1998; 317: 609–10.
 2002 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 8 (Suppl. 2), 107–128
128 Clinical Microbiology and Infection, Volume 8 Supplement 2, 2002
